Opinion EDITORIAL Mark Lebwohl, MD Biosimilars are large complex molecules that are highly simi- et al. The infliximab biosimilar trial reported by Westerkam lar in structure and function to the approved brand-name mol- et al compared 20 patients receiving originator infliximab ecules known as biologics. Biosimilars currently approved in and 14 patients receiving a biosimilar. Although many of the study end points were not statistically significant between the United States that could be used by dermatologists include those for rituximab, the treatment groups, the authors acknowledge that the etanercept, adalimumab, and study was limited by its small sample sizes, retrospective Related articles infliximab. Other approved analysis of data, and allowance of concomitant medications. biosimilars include those for pegfilgrastim, bevacizumab, The authors also acknowledge that, because copay assis- trastuzumab, filgrastim, and epoetin alpha. tance was available for the originator but not for the bio- This issue of JAMA Dermatology includes 2 articles similar, selection bias may have occurred. Despite the small assessing biosimilars of tumor necrosis factor blockers that size of the study, visual analog scale pain scores were more are used to treat a number of dermatologic and nonderma- statistically significantly improved for the patients who tologic conditions. Loft
JAMA Dermatology – American Medical Association
Published: Jun 7, 2021
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera